Prasugrel News and Research

RSS
Primary results of CABG sub-analysis presented at ACC meeting

Primary results of CABG sub-analysis presented at ACC meeting

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

New Drug Application for ticagrelor submitted to the FDA

New Drug Application for ticagrelor submitted to the FDA

VerifyNow System, a rapid platelet function assessment platform, evaluated at AHA's Scientific Sessions

VerifyNow System, a rapid platelet function assessment platform, evaluated at AHA's Scientific Sessions

Updated clinical guidelines on Effient treatment for ACS patients

Updated clinical guidelines on Effient treatment for ACS patients

Key findings from AstraZeneca's phase II studies of ticagrelor

Key findings from AstraZeneca's phase II studies of ticagrelor

Quest Diagnostics' DNA testing for gene variants help improve outcomes for stent recipients

Quest Diagnostics' DNA testing for gene variants help improve outcomes for stent recipients

HCRI commences patient enrollment in dual antiplatelet therapy study

HCRI commences patient enrollment in dual antiplatelet therapy study

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

Accumetrics signs a distribution agreement with Grifols for its VerifyNow System in Spain, Portugal and Chile

Accumetrics signs a distribution agreement with Grifols for its VerifyNow System in Spain, Portugal and Chile

Cordis enrolls first patient in the CYPRESS clinical study

Cordis enrolls first patient in the CYPRESS clinical study

University of Maryland researchers perform a  genome-wide association study of ADP-stimulated platelet aggregation

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

Portola Pharmaceuticals' investigational antiplatelet drug elinogrel featured at the ESC Congress 2009

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

FDA to review prasugrel for acute coronary syndromes

FDA to review prasugrel for acute coronary syndromes

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Big question over new blood-clot buster drug Prasugrel

Big question over new blood-clot buster drug Prasugrel